Hormone therapy for hot flashes linked to lower heart disease risk in peri- and early postmenopausal women

A recent study conducted by researchers at Virginia Commonwealth University and the University of Pittsburgh has shed new light on a long‑standing question in women’s health: how hormone therapy used to treat menopausal symptoms influences cardiovascular disease risk during the peri‑ or early postmenopausal period. The multicenter analysis followed thousands of women who initiated hormone therapy within the first five years after menopause, comparing their cardiovascular outcomes with those of women who did not receive hormone treatment.

The investigators found that, when used in the early stages of menopause, hormone therapy was not associated with a statistically significant increase in major cardiovascular events such as heart attack or stroke. However, the study also noted that the risk profile varied with the type of hormone formulation and the duration of use, suggesting that individualized treatment plans remain essential. These findings align with recent evidence that the timing of hormone therapy initiation may be a critical factor in determining cardiovascular safety.

While the study does not eliminate all concerns about hormone therapy, it provides reassuring data for clinicians and patients considering treatment for menopausal symptoms in the peri‑ or early postmenopausal window. The authors emphasize the importance of ongoing monitoring and personalized risk assessment, underscoring that hormone therapy decisions should balance symptom relief with long‑term cardiovascular health.